Who are Ventoline® Evohaler® 100 µg/inhalation pMDI's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Akovaz, Striverdi Respimat, Breo Ellipta, Arcapta Neohaler, Brovana, Foradil.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ventoline-evohaler-100-g-inhalation-pmdi.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-18 · How we verify

Ventoline® Evohaler® 100 µg/inhalation pMDI — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Ventoline® Evohaler® 100 µg/inhalation pMDI (Ventoline® Evohaler® 100 µg/inhalation pMDI) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Short-acting beta-2 adrenergic agonist (SABA). Area: Respiratory / Pulmonology.

marketed Short-acting beta-2 adrenergic agonist (SABA) Beta-2 adrenergic receptor Respiratory / Pulmonology Small molecule Live · refreshed every 30 min

Target snapshot

Ventoline® Evohaler® 100 µg/inhalation pMDI (Ventoline® Evohaler® 100 µg/inhalation pMDI) — Orion Corporation, Orion Pharma. Albuterol (salbutamol) is a short-acting beta-2 adrenergic agonist that relaxes airway smooth muscle to rapidly relieve bronchospasm and improve airflow.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Ventoline® Evohaler® 100 µg/inhalation pMDI TARGET	Ventoline® Evohaler® 100 µg/inhalation pMDI	Orion Corporation, Orion Pharma	marketed	Short-acting beta-2 adrenergic agonist (SABA)	Beta-2 adrenergic receptor
Akovaz	EPHEDRINE		marketed	Norepinephrine Releasing Agent	Beta-2 adrenergic receptor	2016-01-01
Striverdi Respimat	OLODATEROL	Boehringer Ingelheim	marketed	beta2-Adrenergic Agonist	Beta-2 adrenergic receptor	2014-01-01
Breo Ellipta	VILANTEROL	Glaxo Grp Ltd	marketed	beta2-Adrenergic Agonist	Beta-2 adrenergic receptor	2013-01-01
Arcapta Neohaler	INDACATEROL	Novartis	marketed	beta2-Adrenergic Agonist	Beta-2 adrenergic receptor	2011-01-01
Brovana	ARFORMOTEROL	Lupin	marketed	beta2-Adrenergic Agonist	Beta-2 adrenergic receptor	2006-01-01
Foradil	FORMOTEROL	Novartis	marketed	beta2-Adrenergic Agonist	Beta-2 adrenergic receptor	2001-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2027-06-14 — Breo Ellipta · 8511304 · US
2027-10-02 — Breo Ellipta · 9333310 · US
2027-10-23 — Breo Ellipta · 8113199 · US
2027-12-14 — Breo Ellipta · 8511304*PED · US
2027-12-18 — Breo Ellipta · 7488827 · US
2028-02-05 — Breo Ellipta · 8161968 · US
2028-04-02 — Breo Ellipta · 9333310*PED · US
2028-04-23 — Breo Ellipta · 8113199*PED · US
2028-08-05 — Breo Ellipta · 8161968*PED · US
2029-02-26 — Breo Ellipta · 11116721 · US
2029-08-26 — Breo Ellipta · 11116721*PED · US
2030-03-08 — Breo Ellipta · 8534281 · US
2030-09-08 — Breo Ellipta · 8534281*PED · US
2030-10-11 — Breo Ellipta · 8746242 · US
2030-11-29 — Breo Ellipta · 9750726 · US
2030-11-29 — Breo Ellipta · 11090294 · US
2031-04-11 — Breo Ellipta · 8746242*PED · US

Sponsor landscape (Short-acting beta-2 adrenergic agonist (SABA) class)

AstraZeneca · 1 drug in this class
GlaxoSmithKline · 1 drug in this class
Khyber Teaching Hospital · 1 drug in this class
Orion Corporation, Orion Pharma · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Ventoline® Evohaler® 100 µg/inhalation pMDI — Competitive Intelligence Brief. https://druglandscape.com/ci/ventoline-evohaler-100-g-inhalation-pmdi. Accessed 2026-05-18.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab